Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cigna Corp (CI) vs GeneDx Holdings Corp (WGS) Price & Performance

Cigna CorpTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Cigna Corp vs GeneDx Holdings Corp — how do they compare? Cigna Corp trades at $272.72 (market cap $73.56B), while GeneDx Holdings Corp trades at $81.74 (market cap $2.32B). The key difference: Cigna Corp is far larger — about 31.7× GeneDx Holdings Corp's market cap, and Cigna Corp pays a 2.24% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.

CIWGS
Market Cap
$73.56B$2.32B
Sector
HealthTechnology
52-Week High
$311.00$167.51
52-Week Low
$244.41$34.51
Enterprise Value
$98.27B$2.35B
Dividend Yield
2.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cigna Corp

Cigna (CI) trades at $282.49, up 2.63% with strong earnings beats in recent quarters. The stock shows bearish technical signals but benefits from low valuation ratios like a P/E of 11.68 and P/S of 0.27. Recent Q2 2026 results exceeded expectations, with EPS of $7.78 beating estimates, and the company raised its full-year guidance to at least $30.45 adjusted EPS, reflecting robust growth in health services and insurance segments.

The outlook is positive due to consistent earnings outperformance and raised guidance, though technical weakness and competitive pressures pose risks. Analyst consensus is strongly bullish with a $338.90 price target, indicating ~20% upside potential from current levels, supported by dividend payments and institutional accumulation.

GeneDx Holdings Corp

GeneDx Holdings Corp. (WGS) trades at $77.08, up 10.76% today, showing strong momentum despite negative profitability metrics. The stock exhibits bullish technical signals with support at $72 and resistance at $80. Recent Q2 2026 earnings beat expectations with $0.01 EPS versus -$0.19 estimate, while revenue reached $114.4 million. However, the company faces significant challenges with a -23.4% net income margin and ongoing securities class action litigation.

Investment outlook remains cautiously optimistic given strong analyst support (90.9% buy rating) and $79.25 consensus price target. Key opportunities include growing genomic testing volumes and improved operational efficiency, while risks center on profitability challenges, legal liabilities, and high valuation multiples that may not justify current fundamentals.

Returns comparison

Trailing returns across standard periods

About Cigna Corp

Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.

Read more on CI

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS